AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06565533 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR)
Description: Standing on a lifelike full-sized basketball court, they observe smooth flooring and clear markings. Teammates and opponents don variously colored uniforms, while referees stand ready at the sidelines. Referees position teammates and opponents around the basket as participants feel the texture and weight of the basketball in their hands, as if gripping it for real. The sounds of cheering spectators and encouraging shouts from teammates and coaches further enhance their focus. Participants adjust their stance, noticing beads of sweat trickling down their arms as they prepare for the FT. With bent knees, they ready themselves for the shot, exerting every ounce of their strength as the ball leaves their hands and soars towards the basket. As the ball accurately swishes through the net, the crowd erupts into thunderous applause, and the scoreboard's change in score brings an overwhelming sense of joyous victory.
Study NCT05809895 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: 200 mg intravenously (IV) Q3W
Study NCT05809895 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tislelizumab
Description: 200 mg intravenously (IV) Q3W
Study NCT05809895 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Tislelizumab
Description: 200 mg intravenously (IV) Q3W
Study NCT05809895 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 90 mg/m2 intravenously (IV) on Days 1, 8 and 15 every 28 days
Study NCT05809895 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: 90 mg/m2 intravenously (IV) on Days 1, 8 and 15 every 28 days
Study NCT05809895 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Paclitaxel
Description: 90 mg/m2 intravenously (IV) on Days 1, 8 and 15 every 28 days
Study NCT05809895 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: 100 mg/m2 intravenously (IV) on Days 1, 8 and 15 every 28 days
Study NCT05809895 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nab-paclitaxel
Description: 100 mg/m2 intravenously (IV) on Days 1, 8 and 15 every 28 days
Study NCT05809895 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Nab-paclitaxel
Description: 100 mg/m2 intravenously (IV) on Days 1, 8 and 15 every 28 days
Study NCT05809895 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC 2 intravenously (IV) on Days 1 and 8 every 21 days
Study NCT05809895 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: AUC 2 intravenously (IV) on Days 1 and 8 every 21 days
Study NCT05809895 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Carboplatin
Description: AUC 2 intravenously (IV) on Days 1 and 8 every 21 days
Study NCT05809895 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: normal saline intravenously (IV) Q3W
Study NCT05809895 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: 200 mg intravenously (IV) Q3W
Study NCT05809895 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1000 mg/m2 intravenously (IV) on Days 1 and 8 every 21 days
Study NCT05809895 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: 1000 mg/m2 intravenously (IV) on Days 1 and 8 every 21 days
Study NCT05809895 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Gemcitabine
Description: 1000 mg/m2 intravenously (IV) on Days 1 and 8 every 21 days
Study NCT05645016 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: COEST
Description: Adapted version of our COEST training, targeting Black church members.
Study NCT06556576 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IMPROVA Platform
Description: Adolescents, teachers, school staff, and parents will have access to a variety of content aimed at promoting the mental health and well-being of adolescents that can be accessed through the IMPROVA platform, an innovative eHealth solution that can be accessed via app and website.~Students: around 20 modules that can be grouped in five categories: Me and My Emotions, Me and My Body, Me and My Relationships, School and Free time, and Finding my Strengths.~Teachers and other school staff: 1) pedagogical and health-related modules to support their students and teaching practices; 2) modules to manage their own health; 3) tutoring sessions: resources (lessons plans) for tutors (teachers or other school staff) for carrying out a discussion with students in topics related to the students' health and wellbeing.~Parents: contents on promoting positive relationships, emotional and social skills, positive behaviour, behaviours to support wellbeing, and family-school collaboration.
Study NCT05068700 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Integrated Pulmonary Index
Description: Medtronic Capnostream 35p monitoring parameter
Study NCT05068700 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard capnography monitoring
Description: Medtronic Capnostream 35p monitoring parameter
Study NCT05434767 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mobile application
Description: Participants will be instructed on the installation and use of the mobile application on their personal mobile phones. Participants will then have to perform the assigned exercises using the mobile application 3 times daily. Physiotherapists will still perform the required assessment/review, education, and intervention.
Study NCT05434767 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard rehabilitation program
Description: All participants will be seen by physiotherapists in the ward post-TKR surgery and undergo standard inpatient rehabilitation. Patients will be given instructions to perform assigned exercises 3 times daily. Physiotherapists will perform the required assessment/review, education, and intervention.
Study NCT05156164 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kinesio Tape Group
Description: The application of the KT consists of 6 strips of I-shaped tape adhered to the skin areas of the shoulder
Study NCT05156164 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Control Group
Description: KT application on the deltoid but without support function
Study NCT05661071 — intervention group
Intervention type: OTHER
Intervention: Modified Mini Mental Test:
Description: To assess the cognitive function of children
Study NCT05661071 — intervention group
Intervention type: OTHER
Intervention: The Controlled Oral Word Association Test
Description: To assess the cognitive function of children
Study NCT05661071 — intervention group
Intervention type: OTHER
Intervention: The Central Nervous System Vital Signs
Description: To assess the cognitive function of children
Study NCT05661071 — intervention group
Intervention type: OTHER
Intervention: Conners' Parent Rating Scale-48 (Parent Report)
Description: To assess attention-deficit/hyperactivity disorder
Study NCT05661071 — intervention group
Intervention type: OTHER
Intervention: Child Behavior Checklist 6-18 ages (Parent Report)
Description: To assesses both child adaptive behaviors and problem behaviors.
Study NCT05661071 — intervention group
Intervention type: OTHER
Intervention: Strengths and Difficulties Questionnaire (Self-Reported)
Description: It is a brief emotional and behavioural screening questionnaire for children and young people.
Study NCT05661071 — intervention group
Intervention type: OTHER
Intervention: Brooke Lower Extremity Functional Classification
Description: To determine the functional status of the lower extremity
Study NCT05661071 — intervention group
Intervention type: OTHER
Intervention: Motor Function Measurement-32 Items
Description: To assessment of motor function and progression of weakness in neuromuscular disorders
Study NCT05661071 — intervention group
Intervention type: OTHER
Intervention: Four Square Step Test
Description: A test of dynamic balance and coordination that clinically assesses the participant's ability to step over objects forward, sideways, and backwards.
Study NCT05661071 — intervention group
Intervention type: OTHER
Intervention: Six Minutes Walk Test
Description: It evaluates the walking function and physical capacity of children at the submaximal level.
Study NCT05661071 — intervention group
Intervention type: OTHER
Intervention: Timed Performance Test
Description: 10 meters Walk\& Run Test, Gower's(from a supine to a standing position), Right\& Left Leg Standing, Ascent/Descent of 4 Steps
Study NCT05285943 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olive oil cream
Description: Olive oil prepared in a base cream to be applied to irradiated areas.
Study NCT05285943 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Betamethasone Valerate Cream
Description: Betamethasone valerate prepared in a base cream to be applied to irradiated areas.
Study NCT05285943 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Base Cream
Description: The base cream used for preparation of both the betamethasone valerate cream and olive cream will be used as a placebo control to be applied to irradiated areas.
Study NCT06567756 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CSPO
Description: The distal rectum is freed to the entrance of the internal and external sphincter space, and then an oblique resection line is designed under direct vision according to the tumor site and shape, ensuring that the distal and lateral margins are not less than 1 cm, and preserving the contralateral dentate line and the intestinal wall as much as possible, and the anastomosis is completed manually or with instruments.
Study NCT06567756 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ISR
Description: Partial, subtotal, or total excision of the internal sphincter and/or a portion of the longitudinal rectal muscle, expansion of the distal rectal excision margin into the anal canal or to the anal verge, and completion of the colo-anal anastomosis manually or instrumentally.
Study NCT04980417 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: concomitant cholecystectomy
Description: delayed cholecystectomy
Study NCT04980417 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: concomitant cholecystectomy
Description: delayed cholecystectomy
Study NCT05898009 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: blood sample for BRCA2 mutation detection
Description: blood sample
Study NCT06647576 — intervention group
Intervention type: DEVICE
Intervention: Spinal Cord Stimulation - In Clinic
Description: Control Group Intervention: In-Person SCS therapy. Device settings, such as pulse width and frequency, will be adjusted during regular clinic visits. Follow-up assessments for pain relief, quality of life, and therapy effectiveness will occur at 1, 3, and 6-month intervals over a 6-month period.
Study NCT06647576 — intervention group
Intervention type: DEVICE
Intervention: Spinal Cord Stimulation - Neurosphere
Description: Test Group Intervention: Test group participants will receive remote monitoring and therapy adjustments through the Neurosphere™ virtual clinic platform. Participants in test group will have trial and end of trial phases in clinic, but further SCS therapy will be performed through Neurosphere. Clinicians will adjust the SCS device settings, including pulse width and burst frequency, remotely. This intervention allows patients to avoid in-person visits while receiving continuous, personalized care, with follow-up assessments at 1, 3, and 6 months over a 6-month period.
Study NCT06641687 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 24% Sucrose
Description: Participants will be given either sugar water (24% sucrose) randomly
Study NCT06641687 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sterile water
Description: Participants will be given sterile water randomly
Study NCT06650280 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hyaluronic Acid (HA)
Description: hyaluronic acid coated implants will be placed in posterior maxilla to evaluate rapid osseointegration
Study NCT06650280 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: nano-hydroxyapatite
Description: nano-hydroxyapatite coated implants will be placed in posterior maxilla to assess rapid osseointegration
Study NCT06650280 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: sandblasted acid etched
Description: SLA coated implants will be placed in posterior maxilla and implant stability will be evaluated
Study NCT06019611 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Percutaneous epidural stimulation
Description: Abbott percutaneous trial lead for epidural neurostimulation (Model 3086)~Abbott clinician programmer for epidural and dorsal root ganglion neurostimulation (Model 3874)~Ripple Neuromed Nomad Neurostimulation System
Study NCT04873830 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: volume stable collagen matrix placement
Description: volume stable collagen matrix placement to augment the buccal defect.in class I siebert at the same time of implant placement
Study NCT04873830 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: connective tissue grafting
Description: connective tissue placement to augment the buccal defect.in class I siebert at the same time of implant placement
Study NCT04896697 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vilastobart (XTX101)
Description: vilastobart (XTX101) monotherapy
Study NCT04896697 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: 1200 mg administered every 3 weeks in combination with vilastobart (XTX101)
Study NCT04896697 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vilastobart (XTX101)
Description: In combination with Atezolizumab
Study NCT05492877 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitiperstat (AZD4831)
Description: Oral dosage, once daily.
Study NCT05492877 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral dosage, once daily.
Study NCT06650943 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nursing Consultation in Weight Management and Metabolic syndrome
Description: Based on the Carbohydrate-insulin Theory
Study NCT06653738 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin 25 MG
Description: Once daily per os for 3 years
Study NCT06653738 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Once daily per os for 3 years
Study NCT06653738 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized dietary counseling
Description: Personalized dietary counseling based on repeat 24-hr urine collections and dietary assessments for 3 years
Study NCT06653738 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Personalized dietary counseling
Description: Personalized dietary counseling based on repeat 24-hr urine collections and dietary assessments for 3 years
Study NCT06653738 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Generic dietary counseling
Description: Generic dietary counseling based on current guidelines without 24-hr urine collection results and without specific dietary assessments for 3 years
Study NCT06653738 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Generic dietary counseling
Description: Generic dietary counseling based on current guidelines without 24-hr urine collection results and without specific dietary assessments for 3 years
Study NCT06653868 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: dental implant with bone augmentation
Description: gap distance augmentation with bone graft
Study NCT06653673 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ChatGPT supported Online Guided Self-Help Program (GSHP)
Description: Guided Self-Help Program (GSHP)~The Guided Self-Help Program (GSHP) was developed by Fairburn and Carter for patients with binge eating disorder and later adapted to address various eating behaviors, forming an intervention protocol. GSHP modules consist of:~Starting self-monitoring, Establishing regular eating patterns, Applying the mindful eating rule and developing alternatives to emotional eating, Practicing problem-solving exercises, Addressing diet-related issues and body image, and Termination modules.~Session Structure:~Session 1 focuses on tracking eating patterns and raising self-awareness about eating habits. Individuals are asked to maintain a daily record via a shared Google Forms link. This food diary is later processed through ChatGPT, and personalized feedback is provided.~Session 2 provides psychoeducation on developing regular eating patterns. It emphasizes recognizing hunger and satiety cycles and reducing triggers. Participants are asked to log their meals daily
Study NCT06652087 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifaximin
Description: Rifaximin (Alfa Normix®, Alfa Wassermann S.P.A., Italy, registration number LS-001993, 08/31/2010) in standard doses of 200 mg 3 times a day for 7 days
Study NCT06652087 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard HFpEF treatment
Description: diuretic, including an aldosterone antagonist; sodium-glucose cotransporter-2 inhibitor
Study NCT06652087 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard HFpEF treatment
Description: diuretic, including an aldosterone antagonist; sodium-glucose cotransporter-2 inhibitor
Study NCT06338176 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: OPTIMUS-SAB clinical care pathway
Description: Activation of SAB clinical care pathway within EMR system.
Study NCT05409157 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986166
Description: Specified dose on specified days
Study NCT05409157 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bisacodyl
Description: Specified dose on specified days
Study NCT05802147 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: skin-to-skin contact
Description: skin-to-skin contact
Study NCT05972434 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sunscreen A
Description: Participants will apply sunscreen A topically.
Study NCT05972434 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sunscreen B
Description: Participants will apply sunscreen B topically.
Study NCT05494125 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: Patients will receive a continuous infusion of ropivacaine through bilateral ESP catheters
Study NCT05494125 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will receive a continuous infusion of saline solution through bilateral ESP catheters
Study NCT04655404 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Larotrectinib
Description: 1. Larotrectinib monotherapy x2 cycles followed by disease evaluation~2. Larotrectinib with or without chemotherapy backbone
Study NCT06291597 — intervention group
Intervention type: OTHER
Intervention: Vaping
Description: Participants use their vaping products at their own discretion and their intake is monitored via questionnaires.
Study NCT04655404 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Larotrectinib surgical
Description: 1. Surgical cohort: Larotrectinib x 3-5 days prior to definitive surgery followed by Larotrectinib monotherapy x2 cycles followed by disease evaluation~2. Larotrectinib with or without chemotherapy backbone
Study NCT06573840 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NeuroGlove
Description: NeuroGlove is a non-invasive device that provides peripheral somatosensory stimulation to the hand. NeuroGlove provides sensory stimulation in the form of pneumatic puffs of air.
Study NCT06538961 — intervention group
Intervention type: OTHER
Intervention: Collection of blood samples
Description: the collection of blood samples by finger stick, heel stick, ear stick, or venipuncture from individuals where the amount of blood does not exceed allowable amounts (see help).
Study NCT06100068 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mental Exercises and Temporal Alteration
Description: Mental exercises during L-DIBH to distort the awareness of passage of time
Study NCT06100068 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mental Exercises and Temporal Alteration
Description: Mental exercises during L-DIBH to distort the awareness of passage of time
Study NCT04805983 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-984923
Description: Day 1: Admission, administration of study drug, and 2 night in-patient stay; Day 3: Discharge following the completion of all scheduled procedures.
Study NCT06538961 — intervention group
Intervention type: OTHER
Intervention: Data Collection
Description: Donor and Recipient's clinical information including clinical history, demographic characteristics labs, and imaging.
Study NCT06538961 — intervention group
Intervention type: OTHER
Intervention: Urine Sample
Description: Post-transplant monthly urine sample collection for 6 months
Study NCT06652165 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zanubrutinib combined with BEAM
Description: zanubrutinib：160mg oral bid D-8-D-2 camustine: 300mg/m2 vgtt qd D-8 etoposide: 100mg/m2/d vgtt q12h D-7-D-4 cytarabine: 200mg/m2/d vgtt q12h D-7-D-4 melphalan: 140mg/m2 vgtt qd D3-D-2
Study NCT06652165 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BEAM
Description: camustine: 300mg/m2 vgtt qd D-8 etoposide: 100mg/m2/d vgtt q12h D-7-D-4 cytarabine: 200mg/m2/d vgtt q12h D-7-D-4 melphalan: 140mg/m2 vgtt qd D3-D-2